Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 3/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476615 | 1.00 | DPP3 (0.55) | DPP3KISS1RIL23RTACR1CXCR4 | |
| SCHEMBL29476405 | 0.92 | KISS1R (0.55) | DPP3KISS1RIL23RCXCR4NTSR2 | |
| SCHEMBL29476509 | 0.92 | KISS1R (0.55) | DPP3KISS1RIL23RCXCR4NTSR2 | |
| SCHEMBL31620052 | 0.91 | C5AR1 (0.57) | DPP3KISS1RIL23RCXCR4NTSR2 | |
| SCHEMBL29546449 | 0.91 | C5AR1 (0.56) | DPP3KISS1RIL23RCXCR4C5AR1 | |
| SCHEMBL29500468 | 0.91 | C5AR1 (0.59) | DPP3KISS1RTACR1CXCR4NTSR2 | |
| SCHEMBL31376716 | 0.89 | CXCR4 (0.55) | DPP3KISS1RIL23RTACR1CXCR4 | |
| SCHEMBL30571131 | 0.89 | C5AR1 (0.59) | DPP3KISS1RC5AR1OPRM1 | |
| SCHEMBL29476408 | 0.89 | KISS1R (0.53) | DPP3KISS1RIL23RCXCR4C5AR1 | |
| SCHEMBL30307184 | 0.89 | CXCR4 (0.56) | DPP3KISS1RTACR1CXCR4NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271400-A | Peptide composition | 节奏制药公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118240012-A | Peptide composition | 节奏制药公司 | 2024-06-25 | — | — | CN | claimed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-105492456-B | Peptide composition | 节奏制药公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12077612-B2 | Peptide compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118271400-A | Peptide composition | 节奏制药公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118240012-A | Peptide composition | 节奏制药公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115957297-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957296-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | DPP3 1147/4885KISS1R 75/4885IL23R 1760/4885 |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | MC4R, MC3R, MC5R | DPP3 190/4885KISS1R 170/4885IL23R 473/4885 |
| US-12077612-B2 | Peptide compositions | MC4R, MC3R, MC5R | DPP3 190/4885KISS1R 170/4885IL23R 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.